The impact of stereoisomerism in a bioequivalence study on two formulations of doxepin

European Journal of Pharmaceutical Sciences

Volumn 4, Issue 3, 1996, Pages 133-138

  Midha, K K ^a,b   Hubbard, J W ^a   Rawson, M ^a   Schwede, R ^c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Geneva Pharmaceuticals   (United States)

Author keywords

Bioequivalence; Doxepin; Geometric isomerism; Metabolites; N Desmethyldoxepin; Stereoisomerism

Indexed keywords

DOXEPIN; DRUG METABOLITE; NORDOXEPIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEREOISOMERISM; VOLUNTEER;

EID: 0030012868     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/0928-0987(95)00039-9     Document Type: Article

References (24)

1. Ariens, E. (1984) Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26, 663-668.
2. Blume, H. and Midha, K. (1993) Bio-International 92, Conference on Bioavailability, Bioequivalence, and Pharmacokinetic Studies. J. Pharm. Sci. 82, 1186-1189.
3. max for absorption rates in investigations of bioequivalence. Int. J. Clin. Pharmacol. Ther. Toxicol. 29, 394-399.
4. max/AUC in investigations of bioequivalence. Int. J. Clin. Pharmacol. Ther. Toxicol. 31, 184-189.
5. Faulkner, R., Pitts, W., Lee, C., Lewis, W. and Fann, W. (1983) Multipledose doxepin kinetics in depressed patients. Clin. Pharmacol. Ther. 34, 509-515.
6. Ghabrial, H., Prakash, C., Tacke, U., Blair, I. and Wilkinson, G. (1991) Geometric isomerism of doxepin during its N-demethylation. Drug Metab. Dispos. 19, 596-599.
7. Green, D. (1978) Clinical importance of doxepin plasma levels. J. Clin. Psychiat. 39, 481-482.
8. Grizzle, J. (1965) The two period change-over design and its use in clinical trials. Biometrics, 21, 467-480.
9. Hrdina, P., Bakish, D., Swenson, S. and Lapierre, Y. (1990) cis-and trans-isomers of doxepin and N-desmethyldoxepin in the plasma of depressed patients treated with doxepin. Therap. Drug Monitor. 12, 129-133.
10. Hubbard, J., Ganes, D., Lim, H. and Midha, K. (1986) Chiral pharmacology and its consequences for therapeutic monitoring. Clin. Biochem. 19, 107-112.
11. Jamali, F., Collins, D., Berry, B., Molder, S., Cheung, R., McColl, K. and Cheung, H. (1991) Comparative bioavailability of two flurbiprofen products: Stereospecific versus conventional approach. Biopharm. Drug Dispos. 12, 435-445.
12. Luo, H., Hawes, E., McKay, G., Korchinski, E. and Midha, K. (1991) The quaternary ammonium-linked glucuronide of doxepin: A major metabolite in depressed patients treated with doxepin. Drug Metab. Dispos. 1991, 722-723.
13. Midha, K., Hubbard, J., McKay, G., Hawes, E., Korchinski, E., Gurnsey, T., Cooper, J. and Schwede, R. (1992) Stereoselective pharmacokinetics of doxepin isomers. Eur. J. Clin. Pharmacol. 42, 539-544.
14. Midha, K., Hubbard, J., Rawson, M., and Gavalas, L. (1994) The application of partial areas in assessment of rate and extent of absorption in bioequivalence studies of conventional release products: Experimental evidence. Eur. J. Pharm. Sci. 2, 351-363.
15. Midha, K., Hubbard, J., Yeung, P., Ormsby, E., McKay, G., Hawes, E., Korchinski, E., Gurnsey, T., Rawson, M. and Schwede, R. (1993a) Application of replicate design. In K.M.H. Blume (Ed.), Bio-International: bioavailability, bioequivalence and pharmacokinetics; International Conference of F.I.P. "Bio-International '92" held in Bad Homburg, Germany, May 20-22, 1992. Medpharm Scientific Publishers, Stuttgart, pp. 53-68.
16. Midha, K., Ormsby, E., Hubbard, J., McKay, G., Hawes, E., Gavalas, L. and McGilveray, I. (1993b) Logarithmic transformations in bioequivalence: Application with two formulations of perphenazine. J. Pharm. Sci. 82, 138-144.
17. Pinder, R., Brogden, R., Speight, T. and Avery, G. (1977) Doxepin up-to-date: A review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 13, 161-218.
18. Rosseel, M., Bogaert, M. and Claeys, M. (1978) Quantitative GLC determination of cis-and trans-isomers of doxepin and desmethyldoxepin. J. Pharm. Sci. 67, 802-805.
19. Schall, R., Hundt, H.K.L. and Luus, H.G. (1994) Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies. Int. J. Clin. Pharmacol. Therapeut. 32(12), 633-637.
20. Schuirmann, D. (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15, 657-680.
21. Shu, Y.-Z., Hubbard, J., Cooper, J., McKay, G., Korchinski, E., Kumar, R. and Midha, K. (1990a) The identification of urinary metabolites of doxepin in patients. Drug Metab. Dispos. 18, 735-741.
22. Shu, Y.-Z., Hubbard, J., McKay, G. and Midha, K. (1990b) Identification of phenolic doxepin metabolites from patient urine and rat bile. Drug Metab. Dispos. 18, 1096-1098.
23. Tucker, G., Rostami, A. and Jackson, P. (1993) Metabolite measurement in bioequivalence studies: Theoretical considerations. In K. Midha and H. Blume (Eds.), Bio-International Bioavailability, Bioequivalence and Pharmacokinetics. Medpharm Scientific Publishers, Stuttgart, pp. 163-170.
24. Wainer, I. and Drayer, D. (Eds.) (1988) Drug Stereochemistry, Analytical Methods and Pharmacology. Marcel Dekker, New York.